We are live on ! Find out more
EAM

Eventide Asset Management Portfolio holdings

AUM $6.05B
1-Year Est. Return 76.64%
This Fund
S&P 500
This Quarter Est. Return
+13.36%
1 Year Est. Return
+76.64%
3 Year Est. Return
+247.17%
5 Year Est. Return
+285.6%
10 Year Est. Return
+2,546.71%
AUM
$1.76B
AUM Growth
+$158M
Cap. Flow
+$12.9M
Cap. Flow %
0.73%
Top 10 Hldgs %
26.37%
Holding
139
New
12
Increased
27
Reduced
23
Closed
3

Top Buys

Rank Stock Value
1
ELLI
Ellie Mae Inc
ELLI
+$22.2M
2
VRTX icon
Vertex Pharmaceuticals
VRTX
+$21.9M
3
ASND icon
Ascendis Pharma A/S
ASND
+$16.2M
4
ONCE
Spark Therapeutics, Inc. Common Stock
ONCE
+$13.2M
5
FIVN icon
FIVE9
FIVN
+$12.5M

Top Sells

Rank Stock Value
1
LOXO
Loxo Oncology, Inc
LOXO
+$19M
2
BLUE
bluebird bio
BLUE
+$17M
3
SPLK
Splunk Inc
SPLK
+$10.6M
4
PFPT
Proofpoint, Inc.
PFPT
+$9.51M
5
KITE
Kite Pharma, Inc.
KITE
+$8.81M

Sector Composition

Rank Sector Weight
1 Healthcare 38.21%
2 Technology 13.87%
3 Consumer Discretionary 13.68%
4 Industrials 7.76%
5 Utilities 4.21%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
SYRS
101
DELISTED
Syros Pharmaceuticals, Inc. Common Stock
SYRS
$2.21M 0.13%
15,000
– –
DRNA
102
DELISTED
Dicerna Pharmaceuticals, Inc.
DRNA
$2.17M 0.12%
377,000
– –
CDTX
103
DELISTED
Cidara Therapeutics
CDTX
$2.14M 0.12%
13,200
– –
BHVN
104
DELISTED
Biohaven Pharmaceutical Holding Company Ltd.
BHVN
$1.99M 0.11%
53,240
– –
ABB
105
DELISTED
ABB Ltd
ABB
$1.98M 0.11%
80,000
+12,000
+18% +$287K
CHRS icon
106
Coherus Oncology
CHRS
$227M
$1.94M 0.11%
145,000
– –
JCI icon
107
Johnson Controls International
JCI
$87.2B
$1.85M 0.11%
46,000
+5,000
+12% +$202K
BEP icon
108
Brookfield Renewable
BEP
$9.9B
$1.68M 0.1%
93,825
+2,815
+3% +$50.8K
FHB icon
109
First Hawaiian
FHB
$3.4B
$1.59M 0.09%
52,500
+10,500
+25% +$303K
HMC icon
110
Honda
HMC
$39.9B
$1.54M 0.09%
52,000
+2,000
+4% +$56.4K
BCRX icon
111
BioCryst Pharmaceuticals
BCRX
$2.35B
$1.52M 0.09%
290,000
– –
RARX
112
DELISTED
Ra Pharmaceuticals, Inc. Common Stock
RARX
$1.46M 0.08%
100,000
– –
BDN
113
Brandywine Realty Trust
BDN
$525M
$1.38M 0.08%
79,000
+11,500
+17% +$195K
PAYC icon
114
Paycom
PAYC
$7.53B
$1.38M 0.08%
+18,382
New +$1.32M
CWEN icon
115
Clearway Energy Class C
CWEN
$4.94B
$1.37M 0.08%
71,000
+2,000
+3% +$37K
KALA icon
116
KALA BIO
KALA
$13.6M
$1.37M 0.08%
+24
New +$1.32M
PTCT icon
117
PTC Therapeutics
PTCT
$6.26B
$1.36M 0.08%
+68,200
New +$1.34M
TSM icon
118
TSMC
TSM
$2.09T
$1.31M 0.07%
35,000
-4,000
-10% -$146K
APU
119
DELISTED
AmeriGas Partners, L.P.
APU
$1.1M 0.06%
24,500
+4,500
+23% +$199K
CMTA
120
DELISTED
Clementia Pharmaceuticals Inc.
CMTA
$1.01M 0.06%
+60,000
New +$981K
BG icon
121
Bunge Global
BG
$20.2B
$938K 0.05%
13,500
– –
WBK
122
DELISTED
Westpac Banking Corporation
WBK
$820K 0.05%
32,500
– –
ETN icon
123
Eaton
ETN
$150B
$806K 0.05%
10,500
+1,500
+17% +$113K
GLBL
124
DELISTED
TerraForm Global, Inc. Class A Common Stock
GLBL
$760K 0.04%
160,000
– –
EPIX
125
DELISTED
ESSA Pharma
EPIX
$699K 0.04%
135,971
– –
2 3 4
5
6

Similar funds

HPG
Harvest Portfolios Group Oakville, Ontario, Canada $6.06B AUM 16.63% 1-Year Est. Return
EMPI
Elo Mutual Pension Insurance Espoo, Finland $6.06B AUM 24.33% 1-Year Est. Return
RCG
Ruane, Cunniff & Goldfarb New York $6.03B AUM 12.06% 1-Year Est. Return
JWBC
John W. Bristol & Co New York $6.08B AUM 16.51% 1-Year Est. Return
AAM
Advisors Asset Management Monument, Colorado $6.01B AUM 24.74% 1-Year Est. Return
AA
AQR Arbitrage Greenwich, Connecticut $6.09B AUM 27.01% 1-Year Est. Return
CM
CastleKnight Management New York $6B AUM 121.87% 1-Year Est. Return
CIS
Capital International Sarl Los Angeles, California $6.11B AUM 32.29% 1-Year Est. Return

Eventide Asset Management's Q3 2017 Portfolio in Review

As of Q3 2017, Eventide Asset Management held 139 positions worth $1.76B, up 9.9% from $1.61B the previous quarter. Its ten largest holdings account for 26% of the portfolio.

Eventide Asset Management's Q3 2017 filing shows 12 new, 27 increased, 23 reduced and 3 closed positions. Its largest new stake was Ellie Mae Inc: 242,000 shares worth $19.9M. The largest sale was Loxo Oncology, Inc, an estimated $19M.

By sector, the portfolio is most concentrated in Healthcare at 38% of assets, up from 35% a quarter earlier, followed by Technology and Consumer Discretionary.

  • Eventide Asset Management's largest Q3 2017 buy was Ellie Mae Inc: 242,000 shares worth $19.9M.
  • Eventide Asset Management added most to Vertex Pharmaceuticals in Q3 2017, an estimated $21.9M increase.
  • Eventide Asset Management's biggest Q3 2017 reduction was Loxo Oncology, Inc, cutting an estimated $19M.
  • Eventide Asset Management fully exited Kite Pharma, Inc. in Q3 2017, selling an estimated $8.81M.
  • Eventide Asset Management's ten largest holdings make up 26% of its $1.76B portfolio in Q3 2017.
  • Eventide Asset Management opened 12 new positions and closed 3 in Q3 2017.
  • Eventide Asset Management's portfolio value rose 9.9% quarter-over-quarter to $1.76B.

Based on Eventide Asset Management's 13F filing for Q3 2017, filed 14 Nov 2017.